Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
EurekAlert!

A new CAR-T therapy from Sant Pau achieves positive results in a high proportion of patients with a refractory type of lymphoma

Barcelona, April 29, 2025. Researchers at the Sant Pau Research Institute (IR Sant Pau), in collaboration with the Hospital de Sant Pau and the Josep Carreras Leukaemia Research Institute, have ...
EurekAlert!

New CAR-T Therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...